Verastem, Inc.
A biopharmaceutical company focused on fighting cancer, Verastem makes AVMAPKI FAKZYNJA CO-PACK (avutometinib/defactinib), a treatment for a rare form of ovarian cancer called low-grade serous ovarian cancer that received accelerated FDA approval in 2025. It's also developing VS-7375, an oral drug aimed at tumors driven by a common KRAS mutation. Based in the US, the company concentrates on the RAS/MAPK pathway, a key driver in many cancers.
Sold 2.46M
Bought 100.0K
Granted 600.0K
Granted 869.9K · Bought 1.24M
Bought 95.0K
Bought 345.0K
Bought 250.0K
Bought 100.0K
Bought 100.0K
Granted 600.0K · Bought 21.0K
Granted 1.44M · Bought 9.0K · Sold 232.7K
Granted 142.9K · Bought 18.5K
Bought 218.0K
Granted 150.0K
Granted 1.65M · Bought 1.0K · Sold 127.9K
Granted 133.2K · Sold 27.2K
Granted 108.0K
Granted 85.7K · Bought 1.0K
Granted 52.7K
Granted 52.7K
Granted 52.7K
Granted 52.7K · Bought 2.0K
Granted 52.7K
Granted 50.0K
Bought 46.2K
Granted 58.9K · Sold 14.6K
Granted 785.8K · Sold 87.4K
Bought 26.5K
Bought 10.7K
Granted 20.7K · Bought 7.0K · Sold 11.6K
Bought 3.0K
Bought 3.0K
Bought 2.5K
Bought 2.5K
Bought 2.5K
Bought 2.0K
Bought 750
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Kolchinsky Peter +3 co-filers10% owner · 2 transactions | — | 34.75Mas of Jun 2020 | — | — | 2.46M |
| Ridgeback Capital Investments L.P. +2 co-filers10% owner · 1 transaction | — | 10.07Mas of Mar 2020 | — | — | — |
| Evnin Luke +9 co-filersFormer 10% stockholder · 2 transactions | — | 3.97Mas of Feb 2012 | — | 100.0K | — |
| Longwood Fund, L.P.10% owner · 6 transactions | — | 3.79Mas of Jan 2014 | 600.0K | — | — |
| Westphal Christoph HExecutive Chairman, Director · 77 transactions | — | 2.97Mas of Jul 2015 | 869.9K | 1.24M | — |
| CHP III LP10% owner · 6 transactions | — | 2.33Mas of Jun 2013 | — | 95.0K | — |
| Clarke John KDirector · 10 transactions | — | 2.33Mas of Jun 2013 | — | 345.0K | — |
| CHP III LP +1 co-filer10% owner · 2 transactions | — | 2.23Mas of Jan 2012 | — | 250.0K | — |
| BVP VII Special Opportunity Fund LP +5 co-filersDirector, 10% owner · 4 transactions | — | 1.96Mas of Feb 2012 | — | 100.0K | — |
| Gadicke AnsbertDirector · 5 transactions | — | 1.94Mas of Feb 2012 | — | 100.0K | — |
| Aldrich RichardDirector · 25 transactions | — | 1.25Mas of May 2014 | 600.0K | 21.0K | — |
| Paterson DanPresident and CEO, Director · 81 transactions | — | 591.2K | 1.44M | 9.0K | 232.7K |
| Forrester RobertPresident and CEO, Director · 23 transactions | — | 226.2Kas of Oct 2018 | 142.9K | 18.5K | — |
| Barberich Timothy JDirector · 7 transactions | — | 218.0Kas of Dec 2020 | — | 218.0K | — |
| Neumann FrankChief Medical Officer · 1 transaction | — | 150.0Kas of Jan 2021 | 150.0K | — | — |
| Stuglik Brian MDirector · 45 transactions | — | 137.1K | 1.65M | 1.0K | 127.9K |
| Calkins DanielChief Financial Officer · 40 transactions | — | 117.2K | 133.2K | — | 27.2K |
| Bailey Michael PDirector · 1 transaction | — | 108.0K | 108.0K | — | — |
| Pachter JonathanVP, Head of Research · 6 transactions | — | 62.2Kas of Aug 2014 | 85.7K | 1.0K | — |
| Johnson JohnDirector · 3 transactions | — | 52.7K | 52.7K | — | — |
| Kapur AnilDirector · 3 transactions | — | 52.7K | 52.7K | — | — |
| Robertson MichelleDirector · 3 transactions | — | 52.7K | 52.7K | — | — |
| Rowinsky Eric KDirector · 4 transactions | — | 52.7K | 52.7K | 2.0K | — |
| Tollefson Karin AnnaDirector · 3 transactions | — | 52.7K | 52.7K | — | — |
| Ros MatthewChief Operating Officer · 1 transaction | — | 50.0Kas of Apr 2025 | 50.0K | — | — |
| Termeer Henri ADirector · 4 transactions | — | 46.2Kas of Dec 2014 | — | 46.2K | — |
| Bunn Paul A.Director · 6 transactions | — | 44.3K | 58.9K | — | 14.6K |
| Gagnon Robert E.Director · 40 transactions | — | 41.7K | 785.8K | — | 87.4K |
| Phanstiel S. LouiseDirector · 4 transactions | — | 26.5Kas of Dec 2014 | — | 26.5K | — |
| Lobacki Joseph MExecutive VP & CCO · 2 transactions | — | 10.7Kas of Sep 2018 | — | 10.7K | — |
| Kauffman MichaelDirector · 8 transactions | — | 8.7K | 20.7K | 7.0K | 11.6K |
| Bloom Steven H.Chief Strategy Officer · 1 transaction | — | 3.5Kas of Jun 2018 | — | 3.0K | — |
| Friedman Paul ADirector · 1 transaction | — | 3.0Kas of Dec 2014 | — | 3.0K | — |
| Green John BChief Financial Officer · 4 transactions | — | 2.5Kas of Jun 2015 | — | 2.5K | — |
| Lawton Alison FrancesDirector · 1 transaction | — | 2.5Kas of Nov 2014 | — | 2.5K | — |
| Sherwin Stephen ADirector · 1 transaction | — | 2.5Kas of Dec 2014 | — | 2.5K | — |
| Singh MonicaGeneral Counsel · 2 transactions | — | 2.0Kas of Jun 2015 | — | 2.0K | — |
| Horobin JoannaChief Medical Officer · 1 transaction | — | 750as of Dec 2014 | — | 750 | — |
| Kraus StephenDirector · 4 transactions | — | 0as of Feb 2012 | — | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -355.4K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.